ARS Investment Partners’s Correvio Pharma Corp. Ordinary Shares (Canada) CORV Stock Holding History

ARS Investment Partners’s Portfolio CORV Stock Details CORV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-147,818	Closed	-$61K	–	117
2019 Q4	$61K	Sell	147,818 -67,900	-31%	-$113K	0.01%	112
2019 Q3	$431K	Sell	215,718 -206,405	-49%	-$418K	0.08%	82
2019 Q2	$912K	Buy	422,123 +84,255	+25%	+$215K	0.15%	78
2019 Q1	$1.07M	Buy	337,868 +4,013	+1%	+$13K	0.19%	71
2018 Q4	$831K	Buy	333,855 +54,915	+20%	+$183K	0.18%	75
2018 Q3	$1.12M	Buy	+278,940	New	+$1.23M	0.17%	80

Other funds holding CORV

BCM

Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return

JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

ARS Investment Partners's CORV Position: Q1 2020 in Review

ARS Investment Partners sold out of Correvio Pharma Corp. Ordinary Shares (Canada) (CORV) in Q1 2020, closing a stake of 147,818 shares — an estimated $61K sold.

ARS Investment Partners first reported a position in CORV in Q3 2018 and held it in 6 quarters. The position peaked at $1.12M in Q3 2018. 27 funds tracked by Wall St. Rank hold CORV as of Q1 2020.

ARS Investment Partners reported no remaining Correvio Pharma Corp. Ordinary Shares (Canada) position as of Q1 2020 after selling out during the quarter.
ARS Investment Partners sold 147,818 Correvio Pharma Corp. Ordinary Shares (Canada) shares in Q1 2020, an estimated $61K.
ARS Investment Partners first reported a position in Correvio Pharma Corp. Ordinary Shares (Canada) in Q3 2018 and held it in 6 quarters.
ARS Investment Partners's Correvio Pharma Corp. Ordinary Shares (Canada) position peaked at $1.12M in Q3 2018.
27 funds tracked by Wall St. Rank held Correvio Pharma Corp. Ordinary Shares (Canada) as of Q1 2020.

Based on ARS Investment Partners's 13F filing for Q1 2020, filed 12 May 2020.